• Consensus Rating: Buy
  • Consensus Price Target: $600.00
  • Forecasted Upside:
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New Biophytis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BPTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BPTS

Analyst Price Target is $600.00
▲ +∞ Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Biophytis in the last 3 months. The average price target is $600.00, with a high forecast of $600.00 and a low forecast of $600.00. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for BPTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Biophytis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/16/2023HC WainwrightReiterated RatingBuy ➝ Buy$600.00Low
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$600.00Low
2/27/2023HC WainwrightReiterated RatingBuy$6,000.00Low
2/3/2023HC WainwrightReiterated RatingBuy$6,000.00Low
7/5/2022HC WainwrightReiterated RatingBuy$6,000.00N/A
10/25/2021HC WainwrightReiterated RatingBuyHigh
(Data available from 6/24/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Biophytis logo
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $13.37
Low: $8.22
High: $19.56

52 Week Range

Now: N/A

Volume

18,500 shs

Average Volume

7,291 shs

Market Capitalization

$2.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Biophytis?

The following Wall Street research analysts have issued research reports on Biophytis in the last twelve months: HC Wainwright.
View the latest analyst ratings for BPTS.

What is the current price target for Biophytis?

1 Wall Street analysts have set twelve-month price targets for Biophytis in the last year. Their average twelve-month price target is $600.00. HC Wainwright has the highest price target set, predicting BPTS will reach $600.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $600.00 for Biophytis in the next year.
View the latest price targets for BPTS.

What is the current consensus analyst rating for Biophytis?

Biophytis currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BPTS will outperform the market and that investors should add to their positions of Biophytis.
View the latest ratings for BPTS.

What other companies compete with Biophytis?

How do I contact Biophytis' investor relations team?

Biophytis' physical mailing address is SORBONNE UNIVERSITY BC 9 BATIMENT A 4EME ETAGE 4 PLACE JUSSIEU, PARIS I0, 75252. The company's listed phone number is 33-1-44-37-23-00. The official website for Biophytis is www.biophytis.com. Learn More about contacing Biophytis investor relations.